Stereotactic Body Radiotherapy for Frail Patients with Primary Renal Cell Carcinoma: Preliminary Results after 4 Years of Experience - Archive ouverte HAL Access content directly
Journal Articles Cancers Year : 2021

Stereotactic Body Radiotherapy for Frail Patients with Primary Renal Cell Carcinoma: Preliminary Results after 4 Years of Experience

(1) , (2) , (2) , (3) , (2) , (4) , (5) , (2) , (2) , (1) , (2) , (2) , (1, 6, 7)
1
2
3
4
5
6
7

Abstract

Introduction: The aim of this study was to report the oncological outcomes and toxicity of stereotactic body radiotherapy (SBRT) to treat primary renal cell carcinoma (RCC) in frail patients unfit for surgery or standard alternative ablative therapies. Methods: We retrospectively enrolled 23 patients who had SBRT for primary, biopsy-proven RCC at our tertiary center between October 2016 and March 2020. Treatment-related toxicities were defined using CTCAE, version 4.0. The primary outcome was local control which was defined using the Response Evaluation Criteria in Solid Tumors. Results: The median age, Charlson score and tumor size were 81 (IQR 79–85) years, 7 (IQR 5–8) and 40 (IQR 28–48) mm, respectively. The most used dose fractionation schedule was 35 Gy (78.3%) in five or seven fractions. The median duration of follow-up for all living patients was 22 (IQR 10–39) months. Local recurrence-free survival, event-free survival, cancer-specific survival and overall survival were 96 (22/23), 74 (18/23), 96 (22/23) and 83% (19/23), respectively. There were no grade 3–4 side effects. No patients required dialysis during the study period. No treatment-related deaths or late complications were reported. Conclusion: SBRT appears to be a promising alternative to surgery or ablative therapy to treat primary RCC in frail patients.

Dates and versions

hal-03519966 , version 1 (10-01-2022)

Identifiers

Cite

Laure Grelier, Michael Baboudjian, Bastien Gondran-Tellier, Anne-Laure Couderc, Robin Mcmanus, et al.. Stereotactic Body Radiotherapy for Frail Patients with Primary Renal Cell Carcinoma: Preliminary Results after 4 Years of Experience. Cancers, 2021, 13 (13), pp.3129. ⟨10.3390/cancers13133129⟩. ⟨hal-03519966⟩
27 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More